Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces
- 1 August 1998
- journal article
- clinical trial
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 712 (1-2), 225-235
- https://doi.org/10.1016/s0378-4347(98)00147-9
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical developmentBritish Journal of Cancer, 1997
- Glucuronidation of SN‐38, the Active Metabolite of Irinotecan, by Human Hepatic MicrosomesBasic & Clinical Pharmacology & Toxicology, 1997
- Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver CarboxylesteraseBiochemical Pharmacology, 1996
- Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecanCancer Chemotherapy and Pharmacology, 1995
- Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineCancer Chemotherapy and Pharmacology, 1995
- Metabolism of Irinotecan to SN-38 in a Tissue-Isolated Tumor Model.Biological & Pharmaceutical Bulletin, 1995
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties.Journal of Pharmacobio-Dynamics, 1991
- Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivoCancer Chemotherapy and Pharmacology, 1988